LSA
ALDX icon

Leonteq Securities AG’s Aldeyra Therapeutics ALDX Stock Holding History

Leonteq Securities AG’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,000
Closed -$34K – 1128
2021
Q2 		$34K Buy
+3,000
New +$36.1K ﹤0.01% 884

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Leonteq Securities AG's ALDX Position: Q3 2021 in Review

Leonteq Securities AG sold out of Aldeyra Therapeutics (ALDX) in Q3 2021, closing a stake of 3,000 shares — an estimated $34K sold.

Leonteq Securities AG first reported a position in ALDX in Q2 2021 and held it in 1 quarter. The position peaked at $34K in Q2 2021. 117 funds tracked by Wall St. Rank hold ALDX as of Q3 2021.

  • Leonteq Securities AG reported no remaining Aldeyra Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Leonteq Securities AG sold 3,000 Aldeyra Therapeutics shares in Q3 2021, an estimated $34K.
  • Leonteq Securities AG first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 1 quarter.
  • Leonteq Securities AG's Aldeyra Therapeutics position peaked at $34K in Q2 2021.
  • 117 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2021.

Based on Leonteq Securities AG's 13F filing for Q3 2021, filed 26 Mar 2026.